menu
    • menu

    Find Cabazitaxel manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 30
    cabazitaxel

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    35

    API Suppliers

    20

    USDMF

    0

    CEP/COS

    0

    JDMF

    5

    EU WC

    0

    KDMF

    8

    NDC API

    0

    VMF

    21

    Listed Suppliers

    2INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    1

    Others

    FINISHED DOSAGE FORMULATIONS

    101

    FDF Dossiers

    12

    FDA Orange Book

    57

    Europe

    5

    Canada

    8

    Australia

    4

    South Africa

    15

    Listed Dossiers

    30PROSPECTS

    64DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    10

    US Patents

    0

    US Exclusivities

    1

    Health Canada Patents
    API/FDF Prices: Book a Demo

    API REF. PRICE (USD/KG)

    $
    $ 347,489

    GLOBAL SALES INFORMATION

    US Medicaid

    6,064,538

    Annual Reports

    4,405

    Regulatory FDF Prices

    MARKET PLACE

    14

    API

    2

    FDF

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    31

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 183133-96-2, Jevtana, Taxoid xrp6258, Txd 258, Xrp-6258, Cabazitaxelum
    Molecular Formula
    C45H57NO14
    Molecular Weight
    835.9  g/mol
    InChI Key
    BMQGVNUXMIRLCK-OAGWZNDDSA-N
    FDA UNII
    51F690397J
    Cabazitaxel
    Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).
    Cabazitaxel is a Microtubule Inhibitor. The physiologic effect of cabazitaxel is by means of Microtubule Inhibition.
    1 2D Structure

    Cabazitaxel

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
    2.1.2 InChI
    InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1
    2.1.3 InChI Key
    BMQGVNUXMIRLCK-OAGWZNDDSA-N
    2.1.4 Canonical SMILES
    CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC
    2.1.5 Isomeric SMILES
    CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC
    2.2 Other Identifiers
    2.2.1 UNII
    51F690397J
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Jevtana

    2. Kabazitaxel

    2.3.2 Depositor-Supplied Synonyms

    1. 183133-96-2

    2. Jevtana

    3. Taxoid Xrp6258

    4. Txd 258

    5. Xrp-6258

    6. Cabazitaxelum

    7. Xrp6258

    8. Xrp 6258

    9. Jevtana (tn)

    10. Nsc-761432

    11. Chebi:63584

    12. Txd-258

    13. 51f690397j

    14. Kabazitaxel

    15. Jevtana Kit

    16. Cabazitaxel (jevtana)

    17. (2ar,4s,4as,6r,9s,11s,12s,12ar,12bs)-12b-acetoxy-9-(((2r,3s)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1h-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl Benzoate.

    18. Cabazitaxel Acetonate

    19. Cabazitaxel Acetonate [jan]

    20. Cabazitaxel Injection

    21. Cabazitaxel [usan:inn]

    22. Jevanta

    23. Txd258

    24. Unii-51f690397j

    25. Rpr 116258a

    26. Rpr-116258a

    27. Cabazitaxel [mi]

    28. Cabazitaxel [inn]

    29. Cabazitaxel (usan/inn)

    30. Cabazitaxel [usan]

    31. Cabazitaxel [vandf]

    32. Cabazitaxel [mart.]

    33. Cabazitaxel [who-dd]

    34. Schembl179674

    35. Cabazitaxel [ema Epar]

    36. Gtpl6798

    37. Chembl1201748

    38. Amy4317

    39. Cabazitaxel [orange Book]

    40. Dtxsid40171389

    41. Ex-a838

    42. Mfcd18827611

    43. Nsc761432

    44. Nsc794609

    45. S3022

    46. Zinc85536932

    47. Akos032947285

    48. Ccg-270519

    49. Cs-0972

    50. Db06772

    51. Nsc 761432

    52. Nsc-794609

    53. Ncgc00346704-01

    54. Ncgc00346704-03

    55. As-75355

    56. Hy-15459

    57. A25044

    58. D09755

    59. Ab01273971-01

    60. Ab01273971_02

    61. Q412963

    62. Sr-01000941585

    63. J-011721

    64. J-519981

    65. Sr-01000941585-1

    66. (((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-((2r,3s)-3-

    67. (1s)-5beta,20-epoxy-9-oxo-7beta,10beta-dimethoxytaxa-11-ene-1,2alpha,4alpha,13alpha-tetraol 2-benzoate 4-acetate 13-[(2r,3s)-2-hydroxy-3-(tert-butoxycarbonylamino)-3-phenylpropionate]

    68. (1s,2s,3r,4s,7r,9s,10s,12r,15s)-4-(acetyloxy)-15-{[(2r,3s)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3),(1)?.0?,?]heptadec-13-en-2-yl Benzoate

    69. (1s,2s,3r,4s,7r,9s,10s,12r,15s)-4-(acetyloxy)-15-{[(2r,3s)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl Benzoate

    70. (2alpha,5beta,7beta,10beta,13alpha)-4-acetoxy-13-({(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl Benzoate

    71. (2ar,4s,4as,6r,9s,11s,12s,12ar,12bs)-12b-acetoxy-9-(((2r,3s)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,1

    72. (2ar,4s,4as,6r,9s,11s,12s,12ar,12bs)-12b-acetoxy-9-(((2r,3s)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1h-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl Benzoate

    73. [(1s,2s,3r,4s,7r,9s,10s,12r,15s)-4-acetyloxy-1-hydroxy-15-[(2r,3s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] Benzoate

    74. 1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-ene-2,4,13-triyl 4-acetate 2-benzoate 13-((2r,3s)-3-(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate)

    75. 1-hydroxy-7.beta.,10.beta.-dimethoxy-9-oxo-5.beta.,20-epoxytax-11-ene-2.alpha.,4,13.alpha.-triyl 4-acetate 2-benzoate 13-((2r,3s)-3-(((tert-butoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate)

    76. Benzenepropanoic Acid, Beta-[[(1,1-dimethylethoxy)carbonyl]amino]-alpha-hydroxy-, (2ar,4s,4as,6r,9s,11s,12s,12ar,12bs)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1h-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester, (alphar,betas)-

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 835.9 g/mol
    Molecular Formula C45H57NO14
    XLogP32.7
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count14
    Rotatable Bond Count15
    Exact Mass835.37790549 g/mol
    Monoisotopic Mass835.37790549 g/mol
    Topological Polar Surface Area202 Ų
    Heavy Atom Count60
    Formal Charge0
    Complexity1690
    Isotope Atom Count0
    Defined Atom Stereocenter Count11
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameJevtana kit
    Active IngredientCabazitaxel
    Dosage FormSolution
    RouteIv (infusion)
    Strength60mg/1.5ml (40mg/ml)
    Market StatusPrescription
    CompanySanofi Aventis Us

    2 of 2  
    Drug NameJevtana kit
    Active IngredientCabazitaxel
    Dosage FormSolution
    RouteIv (infusion)
    Strength60mg/1.5ml (40mg/ml)
    Market StatusPrescription
    CompanySanofi Aventis Us

    4.2 Drug Indication

    For treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.

    FDA Label

    Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

    Treatment of prostate cancer

    Treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Cabaitaxel has anti-tumour properties and is effective against docetaxel-sensitive and -insensitive tumours.

    5.2 FDA Pharmacological Classification
    5.2.1 Active Moiety
    CABAZITAXEL
    5.2.2 FDA UNII
    51F690397J
    5.2.3 Pharmacological Classes
    Established Pharmacologic Class [EPC] - Microtubule Inhibitor
    5.3 ATC Code

    L01CD

    L01CD04

    L01CD04

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01C - Plant alkaloids and other natural products

    L01CD - Taxanes

    L01CD04 - Cabazitaxel

    5.4 Absorption, Distribution and Excretion

    Absorption

    After an intravenous dose of cabazitaxel 25 mg/m2 every three weeks to a population of 170 patients with solid tumors, the mean Cmax in patients with metastatic prostate cancer was 226 ng/mL (CV 107%) and was reached at the end of the one-hour infusion (Tmax). The mean AUC in patients with metastatic prostate cancer was 991 ng.h/mL (CV 34%). Administration with prednisone or prednisolone do not effect the pharmacokinetic profile of cabazitaxel.

    Route of Elimination

    After a one-hour intravenous infusion [14C]-cabazitaxel 25 mg/m2, approximately 80% of the administered dose was eliminated within 2 weeks. Cabazitaxel is mainly excreted in the feces as numerous metabolites (76% of the dose); while renal excretion of cabazitaxel and metabolites account for 3.7% of the dose (2.3% as unchanged drug in urine).

    Volume of Distribution

    The volume of distribution (Vss) was 4,864 L (2,643 L/m2 for a patient with a median BSA of 1.84 m2) at steady state. Compared to other taxanes, penetrates the CNS to a greater extent.

    Clearance

    Cabazitaxel has a plasma clearance of 48.5 L/h (CV 39%; 26.4 L/h/m2 for a patient with a median BSA of 1.84 m2) in patients with metastatic prostate cancer.

    5.5 Metabolism/Metabolites

    Cabazitaxel is extensively metabolized in the liver (>95%), mainly by the CYP3A4/5 isoenzyme (80% to 90%), and to a lesser extent by CYP2C8 which results in 20 different metabolites. Two of these metabolites are active demethylated derivatives of cabaxitaxel and referred to as RPR112698 and RPR123142 respectively. Docetaxel is another metabolite of cabazitaxel. Cabazitaxel is the main circulating moiety in human plasma.

    5.6 Biological Half-Life

    Following a one-hour intravenous infusion, plasma concentrations of cabazitaxel can be described by a three-compartment pharmacokinetic model with -, -, and - half-lives of 4 minutes, 2 hours, and 95 hours, respectively.

    5.7 Mechanism of Action

    Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the interference of mitotic and interphase cellular functions. The cell is then unable to progress further into the cell cycle, being stalled at metaphase, thus triggering apoptosis of the cancer cell.

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648492200,"product":"CABAZITAXEL (TAX INVOICE NO:1905215412 D","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"EVER PHARMA JENA GMBH","customerCountry":"GERMANY","quantity":"0.41","actualQuantity":"0.412","unit":"KGS","unitRateFc":"380000","totalValueFC":"153976.3","currency":"USD","unitRateINR":28485436.893203884,"date":"29-Mar-2022","totalValueINR":"11736000","totalValueInUsd":"153976.3","indian_port":"HYDERABAD AIR","hs_no":"29329990","bill_no":"9303742","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648492200,"product":"CABAZITAXEL (TAX INVOICE NO:1905215413 D","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"EVER PHARMA JENA GMBH","customerCountry":"GERMANY","quantity":"0.21","actualQuantity":"0.205","unit":"KGS","unitRateFc":"380000","totalValueFC":"76660.2","currency":"USD","unitRateINR":28502439.024390247,"date":"29-Mar-2022","totalValueINR":"5843000","totalValueInUsd":"76660.2","indian_port":"HYDERABAD AIR","hs_no":"29329990","bill_no":"9302425","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1656527400,"product":"CABAZITAXEL","address":"12 6 214 A1, YERMARUS CAMP CROSS,H YDERABAD ROAD","city":"RAICHUR,KARNATAKA","supplier":"SHILPA MEDICARE LTD","supplierCountry":"INDIA","foreign_port":"MOSCOW","customer":"PHARMERA LLC","customerCountry":"RUSSIA","quantity":"0.33","actualQuantity":"0.325","unit":"KGS","unitRateFc":"500000","totalValueFC":"160853.1","currency":"USD","unitRateINR":38612307.692307688,"date":"30-Jun-2022","totalValueINR":"12549000","totalValueInUsd":"160853.1","indian_port":"HYDERABAD AIR","hs_no":"29225090","bill_no":"2516407","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"12 6 214 A1, YERMARUS CAMP CROSS,H YDERABAD ROAD, RAICHUR,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1657650600,"product":"CABAZITAXEL","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"UNDISCLOSED","customerCountry":"GERMANY","quantity":"0.39","actualQuantity":"0.389","unit":"KGS","unitRateFc":"380000","totalValueFC":"144913.2","currency":"USD","unitRateINR":29622107.969151668,"date":"13-Jul-2022","totalValueINR":"11523000","totalValueInUsd":"144913.2","indian_port":"HYDERABAD AIR","hs_no":"29329990","bill_no":"2781793","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663266600,"product":"CABAZITAXEL","address":"","city":"","supplier":"SHILPA PHARMA LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"CRISTALLA PRODUCTS QUIMICOS","customerCountry":"BRAZIL","quantity":"0.21","actualQuantity":"208","unit":"GMS","unitRateFc":"375","totalValueFC":"76365.4","currency":"USD","unitRateINR":29423.076923076922,"date":"16-Sep-2022","totalValueINR":"6120000","totalValueInUsd":"76365.4","indian_port":"HYDERABAD AIR","hs_no":"29225090","bill_no":"4211792","productDescription":"API","marketType":"","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663698600,"product":"CABAZITAXEL","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"UNDISCLOSED","customerCountry":"ARGENTINA","quantity":"0.09","actualQuantity":"0.09","unit":"KGS","unitRateFc":"285000","totalValueFC":"25180.6","currency":"USD","unitRateINR":22422222.222222224,"date":"21-Sep-2022","totalValueINR":"2018000","totalValueInUsd":"25180.6","indian_port":"HYDERABAD AIR","hs_no":"29329990","bill_no":"4329421","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663871400,"product":"CABAZITAXEL","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"UNDISCLOSED","customerCountry":"ARGENTINA","quantity":"0.09","actualQuantity":"0.09","unit":"KGS","unitRateFc":"285000","totalValueFC":"24956","currency":"USD","unitRateINR":22222222.222222224,"date":"23-Sep-2022","totalValueINR":"2000000","totalValueInUsd":"24956","indian_port":"HYDERABAD AIR","hs_no":"29329990","bill_no":"4376684","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1668018600,"product":"CABAZITAXEL","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"UNDISCLOSED","customerCountry":"TAIWAN","quantity":"0.03","actualQuantity":"0.03","unit":"KGS","unitRateFc":"270000","totalValueFC":"8074.7","currency":"USD","unitRateINR":21966666.666666668,"date":"10-Nov-2022","totalValueINR":"659000","totalValueInUsd":"8074.7","indian_port":"HYDERABAD AIR","hs_no":"29329990","bill_no":"5367347","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1686681000,"product":"CABAZITAXEL","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"UNDISCLOSED","customerCountry":"TAIWAN","quantity":"0.03","actualQuantity":"0.03","unit":"KGS","unitRateFc":"270000","totalValueFC":"7980.9","currency":"USD","unitRateINR":21866672.099999998,"date":"14-Jun-2023","totalValueINR":"656000.163","totalValueInUsd":"7980.9","indian_port":"HYDERABAD AIR","hs_no":"29329990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1690396200,"product":"CABAZITAXEL - BATCH NO. CBT(E)-23002, MF","address":"S-553, GREATER KAILASH-II,","city":"NEW DELHI","supplier":"SAI PHYTOCEUTICALS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"IN ORDER OF","customerCountry":"ARGENTINA","quantity":"0.04","actualQuantity":"40","unit":"GMS","unitRateFc":"250","totalValueFC":"9867.4","currency":"USD","unitRateINR":20275.000200000002,"date":"27-Jul-2023","totalValueINR":"811000.008","totalValueInUsd":"9867.4","indian_port":"DELHI AIR","hs_no":"29420090","bill_no":"0","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"S-553, GREATER KAILASH-II,, NEW DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1690482600,"product":"CABAZITAXEL","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"UNDISCLOSED","customerCountry":"ARGENTINA","quantity":"0.09","actualQuantity":"0.087","unit":"KGS","unitRateFc":"270000","totalValueFC":"23056.5","currency":"USD","unitRateINR":21781606.241379313,"date":"28-Jul-2023","totalValueINR":"1894999.743","totalValueInUsd":"23056.5","indian_port":"HYDERABAD AIR","hs_no":"29329990","bill_no":"0","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692297000,"product":"CABAZITAXEL","address":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR","city":"Hyderabad","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"NA","customer":"UNDISCLOSED","customerCountry":"GERMANY","quantity":"0.38","actualQuantity":"380","unit":"GMS","unitRateFc":"319.8","totalValueFC":"120575.1","currency":"USD","unitRateINR":26284.210565789475,"date":"18-Aug-2023","totalValueINR":"9988000.015","totalValueInUsd":"120575.1","indian_port":"HYDERABAD ICD","hs_no":"29329990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1707330600,"product":"CABAZITAXEL","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"EVER PHARMA JENA","customerCountry":"GERMANY","quantity":"0.60","actualQuantity":"602","unit":"GMS","unitRateFc":"310","totalValueFC":"184758.7","currency":"USD","unitRateINR":25465.330564784053,"date":"08-Feb-2024","totalValueINR":"15330129","totalValueInUsd":"184758.7","indian_port":"Hyderabad Air","hs_no":"29329990","bill_no":"7362437","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1711650600,"product":"PHARMACEUTICAL API CABAZITAXEL","address":"5\/502, GARDEN ESTATE,","city":"THANE, MAHARASHTRA.","supplier":"AMTEC HEALTH CARE PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"KUALA LUMPUR - INT\\'L","customer":"SUNSHINE WORLDWIDE BUSINESS LTD","customerCountry":"MALAYSIA","quantity":"0.07","actualQuantity":"65","unit":"GMS","unitRateFc":"24447","totalValueFC":"18775.7","currency":"INR","unitRateINR":23985.461538461539,"date":"29-Mar-2024","totalValueINR":"1559055","totalValueInUsd":"18775.7","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"8734038","productDescription":"API","marketType":"","country":"MALAYSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"5\/502, GARDEN ESTATE,, THANE, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716575400,"product":"CABAZITAXEL(QTY:165 GMS)","address":"2ND FLOOR, SERENE CHAMBERS,","city":"","supplier":"LAURUS LABS LTD","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"EUROFARMA LABORATRIOS S A","customerCountry":"BRAZIL","quantity":"0.17","actualQuantity":"165","unit":"GMS","unitRateFc":"375","totalValueFC":"60839.3","currency":"USD","unitRateINR":30734.599696969697,"date":"25-May-2024","totalValueINR":"5071208.95","totalValueInUsd":"60839.3","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"1156139","productDescription":"API","marketType":"","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"2ND FLOOR, SERENE CHAMBERS,, ","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1717957800,"product":"CABAZITAXEL IH US","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"UNDISCLOSED","customerCountry":"ARGENTINA","quantity":"0.04","actualQuantity":"0.04","unit":"KGS","unitRateFc":"250000","totalValueFC":"9746.5","currency":"USD","unitRateINR":20340875,"date":"10-Jun-2024","totalValueINR":"813635","totalValueInUsd":"9746.5","indian_port":"Hyderabad Air","hs_no":"29329990","bill_no":"1542034","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1718908200,"product":"CABAZITAXEL","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"EVER PHARMA JENA GMBH","customerCountry":"GERMANY","quantity":"0.19","actualQuantity":"190","unit":"GMS","unitRateFc":"310","totalValueFC":"58173","currency":"USD","unitRateINR":25559.198263157894,"date":"21-Jun-2024","totalValueINR":"4856247.67","totalValueInUsd":"58173","indian_port":"Hyderabad Air","hs_no":"29329990","bill_no":"1845769","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1724265000,"product":"CABAZITAXEL IH BATCH : CBT(E)-24001 MFGDT. : AUG-2024 RETEST DT. : JUL-2026","address":"S-553, GREATER KAILASH-II,","city":"NEW DELHI","supplier":"SAI PHYTOCEUTICALS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, JORGE","customer":"IN ORDER OF","customerCountry":"ARGENTINA","quantity":"0.08","actualQuantity":"80","unit":"GMS","unitRateFc":"195","totalValueFC":"15228.7","currency":"USD","unitRateINR":15967,"date":"22-Aug-2024","totalValueINR":"1277360","totalValueInUsd":"15228.7","indian_port":"Delhi Air","hs_no":"29420090","bill_no":"3390864","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Delhi Air","supplierAddress":"S-553, GREATER KAILASH-II,, NEW DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1727289000,"product":"CABAZITAXEL","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"MYBIOTECH GMBH","customerCountry":"GERMANY","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"1100000","totalValueFC":"108508.3","currency":"USD","unitRateINR":90931318.799999997,"date":"26-Sep-2024","totalValueINR":"9093131.88","totalValueInUsd":"108508.3","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"4354307","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1728844200,"product":"CABAZITAXEL","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"VNUKOVO","customer":"MAKIZ PHARMA LTD","customerCountry":"RUSSIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"12300000","totalValueFC":"73057.3","currency":"INR","unitRateINR":12277500,"date":"14-Oct-2024","totalValueINR":"6138750","totalValueInUsd":"73057.3","indian_port":"Hyderabad Air","hs_no":"29329990","bill_no":"4793104","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1730140200,"product":"CABAZITAXEL","address":"12 6 214 A1 SHILPA HOUSE HYDERABAD ROAD","city":"RAICHUR","supplier":"SHILPA PHARMA LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"BUCHAREST","customer":"ROMPHARM CO","customerCountry":"ROMANIA","quantity":"0.01","actualQuantity":"5","unit":"GMS","unitRateFc":"600","totalValueFC":"2818.1","currency":"USD","unitRateINR":47358.800000000003,"date":"29-Oct-2024","totalValueINR":"236794","totalValueInUsd":"2818.1","indian_port":"Hyderabad Air","hs_no":"29225090","bill_no":"5253813","productDescription":"API","marketType":"","country":"ROMANIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"12 6 214 A1 SHILPA HOUSE HYDERABAD ROAD, RAICHUR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1732473000,"product":"CABAZITAXEL","address":"5\/502, GARDEN ESTATE,","city":"THANE, MAHARASHTRA.","supplier":"AMTEC HEALTH CARE PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"ASKALSA IC VE DIS TICARET LTD","customerCountry":"TURKEY","quantity":"0.13","actualQuantity":"0.125","unit":"KGS","unitRateFc":"20858230","totalValueFC":"30576.3","currency":"INR","unitRateINR":20642230,"date":"25-Nov-2024","totalValueINR":"2580278.75","totalValueInUsd":"30576.3","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"5891861","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"5\/502, GARDEN ESTATE,, THANE, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1738175400,"product":"CABAZITAXEL STANDARD","address":"PLOT NO. 2, SY NO.110,","city":"SECUNDERABAD, TELANGANA.","supplier":"VENKATASAI LIFE SCIENCES","supplierCountry":"INDIA","foreign_port":"LONDON LUTON AIRPOR","customer":"ARC PHARMA","customerCountry":"UNITED KINGDOM","quantity":"0.00","actualQuantity":"1","unit":"GMS","unitRateFc":"1500","totalValueFC":"1505.6","currency":"EURO","unitRateINR":129824.98,"date":"30-Jan-2025","totalValueINR":"129824.98","totalValueInUsd":"1505.6","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"7730938","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO. 2, SY NO.110,, SECUNDERABAD, TELANGANA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1738175400,"product":"CABAZITAXEL STANDARD","address":"PLOT NO. 2, SY NO.110,","city":"SECUNDERABAD, TELANGANA.","supplier":"VENKATASAI LIFE SCIENCES","supplierCountry":"INDIA","foreign_port":"MALTA","customer":"PHARMADOX HEALTHCARE LTD","customerCountry":"MALTA","quantity":"0.00","actualQuantity":"1","unit":"GMS","unitRateFc":"1500","totalValueFC":"1505.6","currency":"EURO","unitRateINR":129824.98,"date":"30-Jan-2025","totalValueINR":"129824.98","totalValueInUsd":"1505.6","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"7730943","productDescription":"API","marketType":"REGULATED MARKET","country":"MALTA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO. 2, SY NO.110,, SECUNDERABAD, TELANGANA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1745173800,"product":"CABAZITAXEL IH US","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"MICROSULES ARGENTINA S A","customerCountry":"ARGENTINA","quantity":"0.06","actualQuantity":"0.06","unit":"KGS","unitRateFc":"235000","totalValueFC":"13789.9","currency":"USD","unitRateINR":19673933.333333336,"date":"21-Apr-2025","totalValueINR":"1180436","totalValueInUsd":"13789.9","indian_port":"Hyderabad Air","hs_no":"29329990","bill_no":"1129378","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1746124200,"product":"CABAZITAXEL","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"MYBIOTECH GMBH","customerCountry":"GERMANY","quantity":"0.05","actualQuantity":"50","unit":"GMS","unitRateFc":"1100","totalValueFC":"54002.6","currency":"USD","unitRateINR":92021.149000000005,"date":"02-May-2025","totalValueINR":"4601057.45","totalValueInUsd":"54002.6","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"1473784","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1747679400,"product":"CABAZITAXEL IH US","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TUTEUR SACIFIA","customerCountry":"ARGENTINA","quantity":"0.08","actualQuantity":"0.075","unit":"KGS","unitRateFc":"270000","totalValueFC":"19985.9","currency":"USD","unitRateINR":22704146.666666668,"date":"20-May-2025","totalValueINR":"1702811","totalValueInUsd":"19985.9","indian_port":"Hyderabad Air","hs_no":"29329990","bill_no":"1997982","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1755282600,"product":"CABAZITAXEL","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"MICROSULES ARGENTINA S A","customerCountry":"ARGENTINA","quantity":"0.04","actualQuantity":"0.04","unit":"KGS","unitRateFc":"242000","totalValueFC":"9384.6","currency":"USD","unitRateINR":20533450,"date":"16-Aug-2025","totalValueINR":"821338","totalValueInUsd":"9384.6","indian_port":"Hyderabad Air","hs_no":"29329990","bill_no":"4479101","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1756405800,"product":"CABAZITAXEL","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ATHENS","customer":"DEMO S A PHARMACEUTICALS INDUSTRY","customerCountry":"GREECE","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"500","totalValueFC":"49114.7","currency":"USD","unitRateINR":42985.07,"date":"29-Aug-2025","totalValueINR":"4298507","totalValueInUsd":"49114.7","indian_port":"Hyderabad Air","hs_no":"29329990","bill_no":"4853180","productDescription":"API","marketType":"REGULATED MARKET","country":"GREECE","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q4","strtotime":1766428200,"product":"CABAZITAXEL","address":"HETERO CORPORATE, NO. 7-2-A2,,INDU","city":"HYDERABAD,TELANGANA","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"APIIC MAHABOOBNAGAR","customer":"HETERO LABS LTD SEZ UNIT II","customerCountry":"INDIA","quantity":"0.84","actualQuantity":"0.84","unit":"KGS","unitRateFc":"55924.5","totalValueFC":"46741.2","currency":"USD","unitRateINR":5008036.8452380961,"date":"23-Dec-2025","totalValueINR":"4206750.95","totalValueInUsd":"46741.2","indian_port":"SEZ\/Mahaboobnagar","hs_no":"29329990","bill_no":"0","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"SEZ\/Mahaboobnagar","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,,INDU, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1671561000,"product":"CABAZITAXEL (QTY- 800 GRAMS )","address":"PLOT NO.2, MAITHRIVIHAR AMEERPET,","city":"HYDERABAD","supplier":"SICHUAN XIELI PHARMACEUTICAL COLTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"EUGIA PHARMA SPECIALITIES LTD","customerCountry":"INDIA","quantity":"0.80","actualQuantity":"0.8","unit":"KGS","unitRateFc":"183000","totalValueFC":"148431.9","currency":"USD","unitRateINR":"15289650","date":"21-Dec-2022","totalValueINR":"12231720","totalValueInUsd":"148431.9","indian_port":"HYDERABAD AIR","hs_no":"29329990","bill_no":"3842085","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"PLOT NO.2, MAITHRIVIHAR AMEERPET,"}]
    29-Mar-2022
    23-Dec-2025
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API/FDF Prices: Book a Demo to explore the features and consider upgrading later

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) ...

    Details:

    Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.


    Lead Product(s): Cabazitaxel,Prednisone

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Cytotoxic Drug

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 30, 2015

    Sanofi Company Banner

    01

    Sanofi

    France
    arrow
    Annual COG
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Cabazitaxel,Prednisone

    Therapeutic Area : Oncology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Me...

    Details : Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    June 30, 2015

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer

    Details:

    Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.


    Lead Product(s): Cabazitaxel,Pegfilgrastim,Prednisolone,Dexchloropheniramine Maleate,Diphenhydramine,Ranitidine,Metoclopramide,Granisetron,

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Cytotoxic Drug

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 12, 2015

    Sanofi Company Banner

    02

    Sanofi

    France
    arrow
    Annual COG
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Cabazitaxel, Pegfilgrastim, Prednisolone, Dexchloropheniramine Maleate, Diphenhydramine

    Therapeutic Area : Oncology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment ...

    Details : Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    May 12, 2015

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) ...

    Details:

    Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.


    Lead Product(s): Cabazitaxel,Prednisone

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Cytotoxic Drug

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 04, 2015

    Sanofi Company Banner

    03

    Sanofi

    France
    arrow
    Annual COG
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Cabazitaxel,Prednisone

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Me...

    Details : Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    March 04, 2015

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

    Details:

    Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Transitional Cell.


    Lead Product(s): Cabazitaxel,Gemcitabine

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Cytotoxic Drug

    Sponsor: Guarionex J. Decastro

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 29, 2014

    Sanofi Company Banner

    04

    Sanofi

    France
    arrow
    Annual COG
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Cabazitaxel,Gemcitabine

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Guarionex J. Decastro

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma o...

    Details : Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Transitional Cell.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    July 29, 2014

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors

    Details:

    Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Nonseminomatous germ cell tumor.


    Lead Product(s): Cabazitaxel,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Cytotoxic Drug

    Sponsor: Gustave Roussy

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 15, 2014

    Sanofi Company Banner

    05

    Sanofi

    France
    arrow
    Annual COG
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Cabazitaxel,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Gustave Roussy

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors

    Details : Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Nonseminomatous germ cell tumor.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    April 15, 2014

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer

    Details:

    Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.


    Lead Product(s): Cabazitaxel,Prednisone,Prednisolone

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Cytotoxic Drug

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 28, 2014

    Sanofi Company Banner

    06

    Sanofi

    France
    arrow
    Annual COG
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Cabazitaxel,Prednisone,Prednisolone

    Therapeutic Area : Oncology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prost...

    Details : Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    February 28, 2014

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer

    Details:

    Taxotere is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.


    Lead Product(s): Docetaxel,Cabazitaxel

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Cytotoxic Drug

    Sponsor: Gustave Roussy

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 24, 2014

    Sanofi Company Banner

    07

    Sanofi

    France
    arrow
    Annual COG
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Docetaxel,Cabazitaxel

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Gustave Roussy

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Can...

    Details : Taxotere is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    January 24, 2014

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors

    Details:

    Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.


    Lead Product(s): Cabazitaxel,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Cytotoxic Drug

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 24, 2012

    Sanofi Company Banner

    08

    Sanofi

    France
    arrow
    Annual COG
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Cabazitaxel,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors

    Details : Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    December 24, 2012

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

    Details:

    Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Nervous System Neoplasms.


    Lead Product(s): Cabazitaxel,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Cytotoxic Drug

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 17, 2012

    Sanofi Company Banner

    09

    Sanofi

    France
    arrow
    Annual COG
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Cabazitaxel,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Ce...

    Details : Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Nervous System Neoplasms.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    December 17, 2012

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel

    Details:

    Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Carcinoma, Transitional Cell.


    Lead Product(s): Cabazitaxel,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase II/ Phase IIIProduct Type: Cytotoxic Drug

    Sponsor: Anjali Zarkar

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 20, 2012

    Sanofi Company Banner

    10

    Sanofi

    France
    arrow
    Annual COG
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Cabazitaxel,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase II/ Phase III

    Partner/Sponsor/Collaborator : Anjali Zarkar

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel

    Details : Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Carcinoma, Transitional Cell.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    August 20, 2012

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Sanofi

    France
    arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    CABAZITAXEL

    Brand Name : JEVTANA KIT

    Dosage Form : SOLUTION;INTRAVENOUS

    Dosage Strength : 60MG/1.5ML (40MG/ML)

    Packaging :

    Approval Date : 2010-06-17

    Application Number : 201023

    Regulatory Info : RX

    Registration Country : USA

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Sanofi

    France
    arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Italy

    Cabazitaxel

    Brand Name : Jevtana

    Dosage Form : Cabazitaxel 60Mg 1 Unit Parenteral Use

    Dosage Strength : 1 vial EV 60 mg 1.5 ml + 1 vial solv 4.5 ml

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Sanofi

    France
    arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Allowed

    Registration Country : Switzerland

    Cabazitaxelum

    Brand Name : Jevtana

    Dosage Form : Solution For Injection

    Dosage Strength : 60mg/1.5ml

    Packaging :

    Approval Date : 06/04/2011

    Application Number : 61543

    Regulatory Info : Allowed

    Registration Country : Switzerland

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Sanofi

    France
    arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Authorized

    Registration Country : Spain

    Water For Injectable Preparations; Cabazitaxel

    Brand Name : Jevtana

    Dosage Form : Concentrate And Solvent For Infusion Solution

    Dosage Strength : 60MG

    Packaging :

    Approval Date : 07-04-2011

    Application Number : 11676001

    Regulatory Info : Authorized

    Registration Country : Spain

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Sanofi

    France
    arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Authorized

    Registration Country : Spain

    Cabazitaxel

    Brand Name : Jevtana

    Dosage Form : Concentrate And Solvent For Infusion Solution

    Dosage Strength : 60MG

    Packaging :

    Approval Date : 28-11-2019

    Application Number : 11676001IP

    Regulatory Info : Authorized

    Registration Country : Spain

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Sanofi

    France
    arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Cabazitaxel

    Brand Name : Jevtana

    Dosage Form : Infusion Solution

    Dosage Strength : 60mg/1.5ml

    Packaging :

    Approval Date : 17-03-2011

    Application Number : 28104713710

    Regulatory Info : Prescription

    Registration Country : Denmark

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Sanofi

    France
    arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Approved

    Registration Country : Sweden

    Cabazitaxel

    Brand Name : Jevtana

    Dosage Form : Infusion Solution

    Dosage Strength : 60mg

    Packaging :

    Approval Date : 17-03-2011

    Application Number : 2.01E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Sanofi

    France
    arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Originator

    Registration Country : South Africa

    Cabazitaxel

    Brand Name : Jevtana

    Dosage Form : INF

    Dosage Strength : 60mg/6ml

    Packaging : 6X1mg/6ml

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Dr. Reddy's Laboratories

    India
    arrow
    DCAT Week
    Lotte New York Palace
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    CABAZITAXEL

    Brand Name : CABAZITAXEL

    Dosage Form : SOLUTION;INTRAVENOUS

    Dosage Strength : 60MG/1.5ML (40MG/ML)

    Packaging :

    Approval Date : 2023-02-10

    Application Number : 207718

    Regulatory Info : RX

    Registration Country : USA

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Dr. Reddy's Laboratories

    India
    arrow
    DCAT Week
    Lotte New York Palace
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : India

    Cabazitaxel

    Brand Name : Cabazitaxel

    Dosage Form : Injectable

    Dosage Strength : 40 mg/ml (1.5 ml)

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Looking for 183133-96-2 / Cabazitaxel API manufacturers, exporters & distributors?

    Cabazitaxel manufacturers, exporters & distributors 1

    100

    PharmaCompass offers a list of Cabazitaxel API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cabazitaxel manufacturer or Cabazitaxel supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cabazitaxel manufacturer or Cabazitaxel supplier.

    PharmaCompass also assists you with knowing the Cabazitaxel API Price utilized in the formulation of products. Cabazitaxel API Price is not always fixed or binding as the Cabazitaxel Price is obtained through a variety of data sources. The Cabazitaxel Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Cabazitaxel

    Synonyms

    183133-96-2, Jevtana, Taxoid xrp6258, Txd 258, Xrp-6258, Cabazitaxelum

    Cas Number

    183133-96-2

    Unique Ingredient Identifier (UNII)

    51F690397J

    About Cabazitaxel

    Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).

    TXD258 Manufacturers

    A TXD258 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of TXD258, including repackagers and relabelers. The FDA regulates TXD258 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. TXD258 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of TXD258 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    TXD258 Suppliers

    A TXD258 supplier is an individual or a company that provides TXD258 active pharmaceutical ingredient (API) or TXD258 finished formulations upon request. The TXD258 suppliers may include TXD258 API manufacturers, exporters, distributors and traders.

    click here to find a list of TXD258 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    TXD258 USDMF

    A TXD258 DMF (Drug Master File) is a document detailing the whole manufacturing process of TXD258 active pharmaceutical ingredient (API) in detail. Different forms of TXD258 DMFs exist exist since differing nations have different regulations, such as TXD258 USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A TXD258 DMF submitted to regulatory agencies in the US is known as a USDMF. TXD258 USDMF includes data on TXD258's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The TXD258 USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of TXD258 suppliers with USDMF on PharmaCompass.

    TXD258 WC

    A TXD258 written confirmation (TXD258 WC) is an official document issued by a regulatory agency to a TXD258 manufacturer, verifying that the manufacturing facility of a TXD258 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting TXD258 APIs or TXD258 finished pharmaceutical products to another nation, regulatory agencies frequently require a TXD258 WC (written confirmation) as part of the regulatory process.

    click here to find a list of TXD258 suppliers with Written Confirmation (WC) on PharmaCompass.

    TXD258 NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing TXD258 as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for TXD258 API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture TXD258 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain TXD258 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a TXD258 NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of TXD258 suppliers with NDC on PharmaCompass.

    TXD258 GMP

    TXD258 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of TXD258 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right TXD258 GMP manufacturer or TXD258 GMP API supplier for your needs.

    TXD258 CoA

    A TXD258 CoA (Certificate of Analysis) is a formal document that attests to TXD258's compliance with TXD258 specifications and serves as a tool for batch-level quality control.

    TXD258 CoA mostly includes findings from lab analyses of a specific batch. For each TXD258 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    TXD258 may be tested according to a variety of international standards, such as European Pharmacopoeia (TXD258 EP), TXD258 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (TXD258 USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search